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The rapid increase in the elderly population is leading to a corresponding increase in the
number of people requiring medical care. To date no comparative study between commu-
nity-acquired pneumonia (CAP) and nursing home-acquired pneumonia (NHAP) has been
reported in the very elderly non-intubated patients. The present study was undertaken to
compare the clinical characteristics and microbial etiology between CAP and NHAP in elderly
patients 85-years old. There were 54 patients with NHAP and 47 with CAP. Performance
status was significantly worse in the NHAP than in the CAP group. Among all patients, the most
frequent pathogens were Chlamydophilia pneumoniae followed by Streptococcus pneumoniae,
Mycoplasma pneumoniae influenza virus and Staphylococcus aureus. The frequency of S. peu-
moniae was significantly higher in NHAP patients than in CAP patients after adjusting for age
and sex. Physical activity, nutrition status and dehydration were significant prognostic factors9 231 5017; fax: þ81 59 231 5225.
ic.mie-u.ac.jp (E.C. Gabazza).
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Community-acquired pneumonia and nursing home-acquired pneumonia 585of pneumonia among all patients. In-hospital mortality was significantly higher in NHAP than in
CAP after adjusting for age and sex. This study demonstrated that the etiology and clinical
outcome differ between CAP and NHAP patients in the very elderly non-intubated population.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
The elderly population has substantially increased in the last
half-century and the proportion of elderly people aged 65
years or over in Japan is expected to reach 30% sometimes
between 2020 and 2030 implying that the number of people
requiring medical care will progressively increase. Pneu-
monia is an important cause of morbidity and is the fourth
leading cause of death in the elderly in Japan and the second
and the primary cause of death in men over 85-years old.1
Pneumonia occurring in nursing homes (nursing home-
acquired pneumonia, NHAP) is thought to be clinically
distinct from community-acquired pneumonia (CAP). NHAP
patients usually have several underlying diseases, poor
nutrition status and perform almost no physical activity. In
additional, NHAP mortality is higher than that of CAP2
because dementia and other neurological disorders such as
restlessness delay the diagnosis and treatment. Many
studies have reported that Streptococcus pneumoniae,
Staphylococcus aureus, and Enterobacteriaceae are the
main pathogens that cause pneumonia in the elderly.3
Infection with Chlamydophilia pneumoniae or viruses has
been only occasionally reported particularly in nursing
homes.4 However, previous reports may not necessarily
reflect the whole picture of pneumonia of the elderly
because it is often difficult to obtain uncontaminated
sputum samples from elderly patients and because
commercial immunoassay kits for measuring titer of anti-
bodies are unavailable. This hypothesis of underestimating
the proportion of pneumonia caused by C. pneumonia and
viruses was verified in our previous prospective study using
non-contaminated sputum and recommended immunoassay
kits).5 There we demonstrated that C. pneumonia and
viruses are actually frequent causes of NHAP in the elderly.
Along with the increase in the elderly population the
number of patients with CAP and NHAP seen by their clinicians
is also increasing. Information on the causative pathogenic
microorganism is very useful for improving the choice of anti-
biotic during empiric therapy of both CAP and NHAP patients.
However, the current clinical guidelines do not provide infor-
mation about the microbial etiology of CAP and NHAP in non-
intubated elderly patients. Having shown in the previous study
that C. pneumonia and viruses often cause pneumonia in the
elderly, we undertook the present study to compare the clin-
ical characteristics and microbial etiology between CAP and
NHAP in elderly patients of at least 85-years old.Methods
Patients
This study was carried out from June 2004 through May 2005
at Kinan General Hospital affiliated with Mie University on268 consecutive patients. All patients gave informed
consent, the study was approved by the Committee for
Ethics and Clinical Investigation of Kinan Hospital, and it
was carried out following the recommendations of the
Helsinki Declaration. The following criteria were used for
diagnosis of pneumonia: 1) the presence of symptoms of
lower respiratory tract infection: fever (>38 C), cough,
purulent sputum or change in character of respiratory
secretions, 2) a radiographic infiltrate compatible with
pneumonia, 3) laboratory findings compatible with the
diagnosis of infection: leukocytosis (>11.0  109/L), leu-
copenia (<3.5  109/L), increased arterial-alveolar
gradient. Out of the 268 patients, only 101 fulfilled the
criteria for entry in this study.
CAP patients were considered those that develop
pneumonia with no recent history of hospitalization (no
history of hospitalization for 2 days within 90 days, no
history of attending hospital or hemodialysis clinics within
30 days, or no history of intravenous antibiotic therapy,
chemotherapy or wound care within 30 days). Patients were
considered to have NHAP when they develop pneumonia
while being a resident of a chronic care facility or nursing
home.
Microbiologic evaluation
Microbiologic examination was performed in sputum, urine
and two samples of blood. Sputum samples were taken into
consideration when Gram staining showed numerous
leukocytes (>25 per high power microscopic field) and few
epithelial cells (<10 per high power microscopic field).
Etiological diagnosis
Microbial diagnosis was based on the results of both culture
and Gram staining. A presumptive diagnosis of causative
pathogen was considered when there was only a positive
growth (107 cfu/ml) in culture of a predominant Gram
positive bacterium from sputum. The etiological diagnosis
was considered as definitive when the following criteria was
fulfilled in the absence or presence of Gram staining and
positive culture of sputum; 1) blood culture positive for
bacteria or fungi (in the absence of an apparent extrap-
ulmonary focus); 2) positive culture for bacteria in samples
of pleural fluid or transthoracic needle aspiration; 3) posi-
tive culture of tuberculosis in respiratory samples; 4)
increase in the serum level of IgM against C. pneumoniae
(1:64) (Microimmunofluorescence, Hitachi Chemical Co.,
Japan), M. pneumoniae (any positive titer) by enzyme-
linked immunosorbent assay (TFB. Inc./Meridian Diagnos-
tics); 5) positive urinary antigen for S. pneumoniae (Binax
NOW Streptococcus pneumoniae kit, Binax Inc, USA) and
Legionella pneumophila (Legionella Urine Antigen EIA,
Biotest AG, Germany); 6) bacterial growth in culture of
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lar lavage fluid (105 cfu/ml). 7) sero-conversion (4-fold
increase in the serum level of IgG from acute phase [level
measured at entry] to convalescence phase) against
C. pneumoniae, C. psittaci (Microimmunofluorescence,
Hitachi Chemical Co., Ltd), Mycoplasma pneumoniae
(Serodia-Myco II, Fujirebio Inc, Japan), Influenza virus A
(H1N1, H3N2) and B (B-1) (Influenza Virus Type A(or B)Hi-
Test Seiken, Denka Seiken Co., Japan), Parainfluenza virus
3 (Parainfluenza Virus Type1w3Hi-Test Seiken, Denka
Seiken Co., Japan). In the present study the diagnosis of
Cytomegalovirus (Cytomegalovirus CF-Test Seiken, Denka
Seiken Co), Respiratory syncitial-virus (Respiratory Syncy-
tial Virus Seiken, Denka Seiken Co., Japan) and Adenovirus
(Adenovirus CF-test Seiken, Denka Seiken Co., Japan) was
based on the (4-fold) sero-conversion measured using
commercial kits; However, the best diagnostic method for
Cytomegalovirus is actually virus isolation from biopsy
samples, and that for Adenovirus is the measurement of
viral antigens. Repeated sero-conversion measurements
were performed for definite diagnosis of Influenza virus and
Parainfluenza virus.Table 1 Patient characteristics.
All patients
n Z 101(%)
NHAP þ
n Z 54
Age yrs 90.3  4.3 91.7 
Range yrs 85e102 85e102
Sex M 45(44.6) 16(29.6
ECOG (1e4) 2.5  0.8 3.0  0
Grade 1 11(10.9) 1(1.9)
Grade 2 35(34.6) 6(11.1)
Grade 3 48(47.5) 41(75.9
Grade 4 7(6.9) 6(11.1)
Influenza vaccination
in last 1 year
79(78.2) 45(83.3
Pneumococcal vaccination
in last 10 years
0 0
Prior antibiotics 27(26.7) 19(35.2
Comorbid illnesses
Cerebro vascular disease 33(32.7) 21(38.9
Chronic pulmonary disease 14(13.9) 8(14.8)
Congestive heart failure 14(13.9) 12(22.2
Diabetes melitus 9(8.9) 2(3.7)
Chronic renal disease 8(7.9) 3(5.6)
Gastrostomy 5(5.0) 3(5.6)
Gasterectomy 4(4.0) 3(5.6)
Malignancy 1(1.0) 0
Psychological disorder 1(1.0) 0
Chronic liver disease 2(2.0) 0
No of comorbidillness
None 13(12.9) 6(11.1)
1 38(37.6) 21(38.9
2 37(36.6) 20(37.0
3 13(12.9) 7(13.0)
All data are presented as n (%) and mean SD umless otherwise state
CAPþ 85: community-acquired pneumonia  85-year-old; M: male; E
a not age and sex adjusted.
b age and sex adjusted.Statistical analysis
Data were expressed as the mean  standard deviation
of the mean and analyzed using StatView software.
Univariate analysis was carried out using the chi-square
test or Fishers exact test for categorical data and the
ManneWhitney U-test for continuous variables. Multivar-
iate analysis for age and sex adjustment was performed by
logistic regression analysis. Prognostic factors were
analyzed by logistic regression. All reported p-values are
two-tailed. A p-value of <0.05 was considered as statisti-
cally significant.
Results
Patient characteristics
This study comprised 101 elderly patients of 85-years old
(Table 1). Among these, there were 54 patients fulfilling the
diagnostic criteria for NHAP and 47 for CAP. The age of the
patients with NHAP was significantly different from that of85
(%)
CAP þ 85
n Z 47(%)
p-valuea p-valueb
5.0 88.7  2.7 0.0012 e
85e95 e e
) 29(61.7) 0.0014 e
.5 2.0  0.7 <0.0001 <0.0001
10(21.3) e e
29(61.7) e e
) 7(14.9) e
1(2.1) e e
) 34(72.3) 0.1819 0.4267
0 e e
) 8(17.0) 0.0396 0.0345
) 12(25.5) 0.1534 0.1789
6(12.8) 0.7663 0.1370
) 2(4.3) 0.0099 0.0756
7(14.9) 0.0778 0.0629
5(10.6) 0.4671 0.6658
2(4.3) >0.9999 0.9273
1(2.1) 0.6211 0.3128
1(2.1) 0.4653 0.9963
1(2.1) 0.4653 0.9958
2(4.3) 0.2190 0.9958
7(14.9) e e
) 17(36.2) e e
) 17(36.2) e e
6(12.8) e e
d. NHAPþ 85: Nursing home-acquired pneumonia  85-year-old;
COG: European Cooperative Oncology Group.
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ative Oncology Group [ECOG]) was significantly worse in the
NHAP than in the CAP group while the frequency of
comorbid diseases was not significantly different between
the groups (Table 1). None of the patients had a pneumo-
coccal vaccination within the last 10 years. Antibiotic
therapy had been given prior to admission to 45 patients
with NHAP and to 8 patients with CAP.
Clinical and laboratory findings at presentation
Fever, sputum and dyspnea were the most common symp-
toms in the patients but there were no differences between
the NHAP and CAP groups. No difference was found in
systolic blood pressure, mean blood pressure, the red blood
cell count, lymphocyte count, or the blood concentrations
of hemoglobin, albumin, and cholinesterase between CAP
and NHAP groups (Table 2).Table 2 Clinical and laboratory findings on presentation.
All patients
nZ 101(%)
NHAPþ
nZ 54(
Symptoms on presentation
Fever 72(71.3) 37(68.5
Sputum production 60(59.4) 36(66.7
Cough 45(44.6) 21(38.9
Dyspnea 47(46.5) 27(50.0
Altered mental status 16(15.8) 11(20.4
Temperature C 37.9 0.88 37.8 0
Heart rate/mm 90.1 17.9 90.4 1
SBP mmHg 130.5 29.9 129.9
DBP mmHg 71.3 18.0 70.1 1
MBP mmHg 101.6 21.3 100.9
RR/min 26.1 7.8 26.3 8
PaO2/FiO2 277.7 93.8 274.9
Red blood cell 104/m 1 350.5 60.8 346.9
Hemoglobin g/dl 11.0 1.76 10.8 1
Hematocrit % 33.2 5.26 32.7 4
White blood cell/ml 10335.6 5163.4 10122.2
Neutrophil/mll 8378.8 4777.1 8303.0
Lymphocyte/mll 1101.1 621.3 1119.1
Total protein mg/dl 62.1 0.68 6.15 0
Albumin g/dl 3.10 0.48 3.01 0
Total cholesterol rng/dl 145.2 74.3 145.9
Cholinesterase IU/l 167.7 77.6 163.5
Creatine phosphokinase IU/1 181.5 266.2 180.8
Blood urea nitrogen mg/dl 28.9 21.6 25.5 1
Creatinine mg/dl 1.10 0.76 0.99 0
Sodium mEq/l 139.6 6.26 139.4
Potassium mEq/l 3.99 0.77 3.87 0
Chloride mEq/l 101.9 6.07 101.4
Glucose mg/dl 139.1 75.6 138.3
C-reactive protein mg/dl 12.5 7.34 11.8 7
AH data are presented as n (%) and mean SD umless otherwise state
CAPþ 85: community-acquired pneumonia  85-year-old; SBP; systoli
pressure, RR: respiratory rate.
a not age and sex adjusted.
b age and sex adjusted.Etiology of pneumonia
A microbiologic diagnosis was established in 78.7% (37/47)
of patients with CAP and in 68.5% (37/54) of patients with
NHAP. The diagnosis was definitive in 68.1% (32/47) and
presumptive in 10.6% (5/47) of patients with CAP, and 66.7%
(36/54) and 1.9% (1/54) of patients with NHAP, respectively
(Table 3). A mixed population of pathogens was detected in
23.4% (11/47) of patients with CAP and 42.6% (23/54) of
patients with NHAP. There was a significant difference in
causative microorganism between the CAP (78.5%) and
NHAP (68.5%) groups. Among all patients, the most frequent
pathogens were C. pneumoniae (32.7%) followed by
S. pneumoniae (27.7%), M. pneumoniae (10.9%) influenza
virus (9%) and S. aureus (6%). The frequency of S. peumo-
niae (35.2 vs. 19.1%) was significantly higher in NHAP
patients than in CAP patients after adjusting for age and
sex. The frequency of C. pneumoniae tended to be higher85
%)
CAPþ 85
nZ 47(%)
p-valuea p-valueb
) 35(74.5) 0.5098 0.1361
) 24(51.1) 0.1112 0.9925
) 24(51.1) 0.2195 0.1524
) 20(42.6) 0.4542 0.2141
) 5(10.6) 0.1815 0.2649
.7 37.9 1.02 0.2971 0.2879
4.3 89.8 21.5 0.7166 0.7174
30.3 131.3 29.6 0.8333 0.7266
7.8 72.6 18.3 0.3728 0.2701
20.7 102.4 22.1 0.6736 0.4781
.5 25.8 7.14 0.9205 0.8087
86.0 281.1 102.8 0.5696 0.4128
57.6 355.0 64.9 0.4320 0.9559
.6 11.3 2.0 0.1210 0.5831
.7 33.9 5.9 0.2434 0.9892
 4909.7 10589.9 5483.6 0.9783 0.9398
4702.0 8465.9 4920.6 0.9241 0.8673
673.8 1080.3 561.4 0.9405 0.4867
.70 6.30 0.66 0.2770 0.4979
.45 3.19 0.49 0.1940 0.2577
40.2 144.4 35.6 0.8443 0.6910
90.7 172.8 58.2 0.0499 0.4665
239.1 182.4 299.0 0.2472 0.8409
9.1 32.8 23.7 0.0216 0.1658
.72 1.23 0.78 0.0054 0.2986
6.70 139.8 578 0.5944 0.8552
78 4.13 0.74 0.0370 0.1445
5.6 102.4 6.57 0.1868 0.6191
75.2 140.2þ 76.9 0.9168 0.6876
.0 13.3 7.70 0.3219 0.3953
d. NHAPþ 85: Nursing home-acquired pneumonia  85-year-old;
c blood pressure, DBP; diastole blood pressure; MBP: mean blood
Table 3 Causative microorganisms.
All patients
nZ 101(%)
NHAPþ 85
nZ 54(%)
CAPþ 85
nZ 47(%)
p-valuea p-valueb
Bacterial pathogens 42(41.6) 21(38.9) 21(44.7) 0.5580 0.6346
Streptococcus pneumoniae 28(27.7) 19(35.2) 9(19.1) 0.0725 0.0283
Staphylococcus aureus (MRSA) 6(5.9) 2(3.7) 4(8.5) 0.4129 0.3616
Enterobacteriaceae 5(5.0) 2(3.7) 3(6.4) 0.6561 0.9703
Pseudomonas aeruginosa 1(1.0) 0 1(2.1) 0.4653 0.9959
Haemophilus influenzae 1(1.0) 0 1(2.1) 0.4653 0.9964
Moraxella catarrhalis 3(3.0) 2(3.7) 1(2.1) 0.9999 0.3656
Anaerobes 1(1.0) 0 1(2.1) 0.4653 0.9960
Others 5(5.0) 2(3.7) 3(6.4) e e
Tuberculosis 0 0 0 e e
Atypical pathogens 43(42.6) 22(40.7) 21(44.7) 0.6896 0.6495
Chlamydophilia pneumoniae 33(32.7) 20(37.0) 13(27.7) 0.3162 0.1686
Chlamydophilia psittaci 4(4.0) 0 4(8.5) 0.0437 0.2141
Mycoplasma pneumoniae 11(10.9) 6(11.1) 5(10.6) >0.9999 0.4173
Legionella pneumophila 0 0 0 e e
Viral pathogens 22(21.8) 15(27.8) 7(14.9) 0.1176 0.4228
Cytomegalovirus 7(6.9) 4(7.4) 3(6.4) >0.9999 0.7703
Influenza virus 9(8.9) 6(11.1) 3(6.4) 0.4976 0.5606
Parainfluenza 3 4(4.0) 3(5.6) 1(2.1) 0.6211 0.6971
Respiratory syncytial 3(3.0) 3(5.6) 0 0.2461 0.9970
Adenovirus 0 0 0 e e
Fungal pathogens 1(1.0) 1(1.9) 0 >0.9999 0.9963
All data are presented as n(%) umless otherwise stated. NHAPþ 85: Nursing home-acquired pneumonia 85-year-old; CAPþ 85:
community-acquired pneumonia 85-year-old.
Numbers include mixed population of pathogens 23 in NHAPþ 85 and in 11 CAPþ 85.
Staphylococcus aureus included methicillin-sensitive 1 and methicillin-resistant 1 in NHAPþ 85, and methicillin-sensitive 1 and
methicillin-resistant 3 in CAPþ 85.
Enterobacteriaceae included K pneumniae 2 in NHAPþ 85, and Escherichia coli 1, Proteus mirabilis 1 and Citrobacter freundii 1 in
CAPþ 85.
Others included Streptococcus agalactiae (Group B) 1, Corynebacterium spp 1 in NHAPþ 85, and Streptococcus agalactiae (Group B) 2,
Corynebacterium spp 1 in CAPþ 85.
Influenza virus included Influenza virus A 3, Influenza 8 5 in NHAPþ 85, and Influenza A 2 and Influenza virus B 2 in CAPþ 85.
Fungal pathogens included Candida albicans 1 in NHAPþ 85.
a not age and sex adjusted.
b age and sex adjusted.
588 T. Maruyama et al.in NHAP patients than in CAP. Occurrence of C. pneumoniae
infection was not seasonal. It was detected almost evenly
throughout the year. Infection by anaerobes was detected
in only one case of CAP even though protected respiratory
sampling was performed (protected specimen brushing, 7
cases; thoracic needle aspiration, 2 cases; pleural effusion
culture, 4 cases) (Table 4).
Prognosis
In-hospital mortality was significantly higher (p Z 0.03) in
NHAP (42.6%) than in CAP (23.4%) after adjusting for age
and sex (Table 5). Multivariate analysis of prognostic factors
for mortality was performed with the following variables:
age, sex, environment (community or nursing home),
performance status (ECOG score), body temperature,
systolic blood pressure, oxygenation index, nutritional
status (albumin), immune status (lymphocyte), dehydration
(blood urea nitrogen). The ECOG score (p Z 0.002, odds
ratio Z 7.527), albumin (p Z 0.0248, odds ratio Z 0.186)
and blood urea nitrogen (p Z 0.0333, odds ratio Z 1.028)were independent and significant predictors of prognosis in
all patients (Table 6). Performance status was significantly
worse in patients with NHAP than in those with CAP
(p < 0.0001) (Table 1).
The ECOG score (p Z 0.0020), albumin and blood urea
nitrogen were independent and significant predictors of
prognosis in all patients (Table 6). Performance status was
significantly worse in patients with NHAP than in those with
CAP.
Therapy
Patterns of antibiotic use were similar in both groups,
although those with NHAP tended to get more dual therapy
and more drugs combined with base therapy than those
with CAP (Table 7). Response to the initial empiric antimi-
crobial therapy was evaluated after three days based on
changes of body temperature, symptoms and white blood
cell count. No substantial difference was observed in
response rates to therapy between the two groups of
patients (Table 7).
Table 4 Method of investigation for causative microorganisms.
All patients
nZ 101(%)
Sputum
culture
nZ 90
Blood
Culture
nZ 87
Pleural
effusion
Culture
nZ 4
Urinary
antigen
test
nZ 96
Serology
IgM
nZ 101
Serology
IgG
nZ 97
BALF
nZ 12
PSB
nZ 7
TNA
nZ 2
Bacterial pathogens 42(41.6) 33 5 28 5 1 1
Streptococcus pneumoniae 28(27.7) 13 1 28 3 1
Staphylococcus auieus (MRSA) 6(5.9) 5 1
Enterobacteriaceae 5(5.0) 3 2
Pseudomonas aeruginosa 1(1.0) 1
Haemophilus influenzae 1(1.0) 1
Moraxella catarrhalis 3(3.0) 3
Anaerobes 1(1.0) 1 1
Others 5(5.0) 4 1
Tuberculosis 0 0
Atypical pathogens 43(42.6) 0 44 6
Chlamydophilia pneumoniae 33(32.7) 33 2
Chlamydophiha psittaci 4(4.0) 4
Mycoplasma pneumoniae 11(10.9) 11 0
Legionella pneumophila 0 0
Viral pathogens 22(21.8) 23
Cytomegalovirus 7(6.9) 7
Influenza virus 9(8.9) 9
Parainfluenza 3 4(4.0) 4
Respiratory syncytial 3(3.0) 3
Adenovirus 0 0
Fungal pathogens 1(1.0) 1 l 1
BALF: bronchoalveolar lavage fluid. PSB: prospected specimen brush, TNA: transthoracic needle aspiration.
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Table 5 Logistic regression analysis to compare prognosis between patients with CAPþ 85 and NHAPþ 85.
Coefficient Standard error Chi-square p-Value Odds Ratio 95% Cl
Age yrs 0.165 0.066 6.328 0.0119 1.179 1.037e1.341
Sex (M) 1.255 0.471 7.101 0.0077 0.285 0.113e0.718
In-hospital mortality 1.056 0.500 4.458 0.0347 2.875 1.079e7.666
NHAPþ 85: nZ 54 (died 23, survived 31).
CAPþ 85: nZ 47 (died 11, survived 36).
590 T. Maruyama et al.Discussion
The primary findings of the current study were: (1) the
prevalence of S. pneumoniae was significantly higher in
NHAP than in CAP patients; (2) the most frequent agent of
pneumonia detected by microimmunofluorescence study in
the very elderly was C. pneumonia; (3) the frequency of
virus including cytomegalovirus was also high; (4) physical
activity, nutrition status and dehydration were significant
prognostic factors of pneumonia in the very elderly
population.
S. pneumoniae has been previously documented as the
primary etiology of CAP in the elderly.2,6 However, the
frequency of S. pneumoniae in patients with NHAP in the
elderly population remains controversial. El-Solh AA et al.
studied intubated patients of 75 years old with NHAP
(n Z 47) or with CAP (n Z 57) and found that S. aureus
(29%) surpassed S. pneumoniae (9%) as the leading patho-
genic agent of NHAP.7 Based on these previous data
obtained from intubated patients, the ATS/IDSA guidelines
suggest that the prevalence of S. pneumoniae is low in
NHAP and that NHAP and HAP have a common etiology.8 In
contrast, the present study was carried out in non-intu-
bated patients and revealed a higher prevalence of S.
pneumoniae in NHAP than in CAP patients. In agreement
with the findings of the present study, Kupronis BA et al.
reported that the incidence of invasive pneumococcal
infections in nursing home residents was about 4-fold
higher than that in the community-living elderly,9 and Lim
et al. reported that the most common pathogen in NHAP
was S. pneumoniae (55%).10 Prior use of antibiotics may also
affect the frequency of S. pneumoniae in the airways. To
avoid this effect, in the present study we used an antigenTable 6 Prognostic factors related to mortality by logistic regr
Prognostic Factor Coefficient Standard error
Age yrs 0.092 0.079
Sex (M) 0.618 0.629
Environment (NHAP) 0.538 0.850
ECOG 2.019 0.653
Temperature C 0.392 0.301
SBP mmHg 0.002 0.010
PaO2/FiO2mmHg 0.002 0.003
Blood urea nitrogen mg/dl 0.027 0.013
Albumin g/dl 1.680 0.748
Lymphocyte/m l 0.0004916 0.001
M: male; NHAP: nursing home-acquired pneumonia; ECOG: Europeantest kit (Binax NOW S. pneumoniae) that has been shown to
be specific for S. pneumoniae and to detect it even in
patients with a prior history of antibiotic therapy.11,12 We
confirmed that using this kit there is no difference in the
prevalence of S. pneumoniae between patients with and
without a history of antibiotic therapy (data not shown).
Outbreaks of C. pneumoniae infection among the elderly
in nursing homes have frequently been reported.3,4 Troy
et al. reported three nursing home outbreaks of C. pneu-
moniae infection where 6 of 25 patients with pneumonia
died; they suggested that close, crowded living environ-
ments might lead to an outbreak of infection and high
morbidity due to underlying concurrent diseases.4 Infection
with C. pneumoniae may even become worse in the elderly
that have underlying co-morbidities and are in poor general
condition. MIF test is the only acceptable method for the
serologic diagnosis of the acute phase of C. pneumoniae
infection,13 but it is available only in limited research
centers. Different methods (e.g. ELISA) are used for this
diagnosis in most general institutions. Therefore, inaccu-
rate frequency of C. pneumoniae in the very elderly has
been reported so far.14 Ngeh J et al. reported in a control
group without infection a seroprevalence of 66% and 17%
for IgG and IgM using ELISA. Bandaru VC et al found in 100
subjects without infection 23% were seropositive for IgG
using the MIF test, and 78.7% were the positive for IgG MIF
antibodies in a group of patients with coronary disease and
9.7% of the participants had sero-conversion based on MIF
studies.15e17 In our present study, the diagnostic criteria for
C. pneumoniae was 4-fold increase in IgG level and 64-fold
increase in IgM level, which is stricter than the interna-
tional diagnostic criteria recommended by the IDSA guide-
lines; however, despite this increase in strictness we foundession.
Chi-square p-Value Odds Ratio 95% Cl
1.352 0.2449 0.912 0.781e1.065
0.966 0.3258 1.855 0.541e6.367
0.400 0.5272 0.584 0.110e3.093
9.550 0.0020 7.527 2.092e27.081
1.698 0.1925 0.676 0.375e1.219
0.052 0.8188 0.998 0.978e1.018
0.271 0.6026 1.002 0.996e1.008
4.531 0.0333 1.028 1.002e1.054
5.039 0.0248 0.186 0.043e0.808
0.887 0.3464 1.000 0.998e1.001
Cooperative Oncology Group; SBP: systolic blood pressure.
Table 7 Empiric antimicrobial therapy and response rate.
All patients
nZ 101(%)
Response
(%)
NHAPþ 85
nZ 64(%)
Response
(%)
CAPþ 85
nZ 47(%)
Response
(%)
No of drug combination
One 24(23.8) 12/24(50.0) 9(16.7) 3/9(33.3) 15(31.9) 9/15(60.0)
Two 71(70.3) 51/71(71.8) 42(77.8) 32/42(76.2) 29(61.7) 19/29(65.5)
Three 6(5.9) 4/6(66.7) 3(5.6) 1/3(33.3) 3(6.4) 3/3(100.0)
Base therapy
2nd-generation cephalosporin 4(4.0) 2/4(50.0) 4(7.4) 2/4(50.0) 0(0) e
3rd-generation cephalosporin 16(15.8) 13/16(81.3) 7(13.0) 4/7(57.1) 9(19.1) 9/9(100.0)
4th-generation cephalosporin 42(41.6) 31/42(73.8) 23(42.6) 17/23(73.9) 19(40.4) 14/19(73.7)
Carbapenem 27(26.7) 12/27(44.4) 15(27.8) 10/15(66.7) 12(25.5) 2/12(16.7)
Penicillin 10(9.9) 8/10(80.0 4(7.4) 2/4(50.0) 6(12.8) 6/6(100.0)
Levofloxacin 2(2.0) 1/2(50.0) 1(1.9) 1/1(100.0) 1(2.1) 0/1(0)
Drugs combined
to base therapy
Macrolide 48(47.5) e 28(51.9) e 20(42.6) e
þ2nd-generation cephalosporin 2 e 2 e e e
þ3rd-generation cephalosporin 6 e 3 e 3 e
þ4th-generation cephalosporin 21 e 10 e 11 e
þcarbapenem 11 e 8 e 3 e
þpenicillin 3 e 2 e 1 e
þ3rd-gen.ceph.þ clindamycin 2 e 1 e 1 e
4th-gen.ceph.þ clindamycin 3 e 2 e 1 e
MINO 11(10.9) e 6(11.1) e 5(10.6) e
þ4th-generation cephalosporin 4 e 3 e 1 e
þcarbapenem 5 e 3 e 2 e
þ3rd-generation cephalosporin 2 e e e 2 e
Clindamycin 23(22.8) e 13(24.1) e 10(21.3) e
þ3rd-generation cephalosporin 3 e 1 e 2 e
þ4th-generation cephalosporin 10 e 8 e 2 e
þcarbapenem 4 e 1 e 3 e
þ3rd-gen.ceph.þmacrolide 2 e 1 e 1 e
þ4th-gen.ceph.þmacrolide 3 e 2 e 1 e
þpenicillinþmacrolide 1 e e e 1 e
Oseltamivir 1(1.0) e 1(1.9) e 0(0) e
þpenicillin 1 e 1 e e e
2nd-generation cephalosporin: cefotiam hydro-chloride, cefmetazole sodium, flomoxef sodium.
3rd-generation cephalosporin: ceftriaxone sodium, ceftazidime.
4th-generation cephalosporin: cefepime dihydrochloride, cefpirome sulfate, cefozopran hydro chloride.
Carbapenem: imipenem/cilastatin, panipenem/betamipron, meropenem trihydrate.
Penicillin: ampicillin sodium - sulbactam sodium (2:1), piperacillin sodium.
Macrolide: clarithromycin, azithromycin, erythromycin.
Community-acquired pneumonia and nursing home-acquired pneumonia 591a high frequency of C. pneumoniae. In addition, we found
neither outbreak nor seasonal C. pneumoniae infection.
This infection was detected almost evenly throughout the
year and it was the commonest etiology of pneumonia in
the very elderly. Overall, these observations suggest
the need to standardize the diagnostic methods of
C. pneumoniae.
It is noteworthy that the frequency of infection caused
by bacterial pathogens of the enterobactericeae and
anaerobes groups was low in the present study. This is
surprising because aspiration is usually considered to be
a cause of pneumonia in the very elderly patients, partic-
ularly in nursing home residents.18 One explanation
commonly given for the low diagnostic yield of infection by
anaerobes is the lack of protected respiratory sampling.
However, in the present study the diagnosis of anaerobeswas low in both NHAP and CAP groups even though pro-
tected respiratory sampling was performed. Regarding the
low rate of enterobacteria, an explanation commonly given
for this is the difficulty in obtaining samples in the elderly
population.
The prevalence of M. pneumoniae has been reported to
be low in the elderly2,8; however, we found a frequency of
10.9% in the present study. Similarly, Riquelme et al. also
reported M. pneumoniae was the causative agent in 4% of
cases of pneumonia in the elderly population.19 These
findings suggest that M. pneumonia should be also consid-
ered as an etiological factor of pneumonia in the very
elderly population.
Viral infection in nursing homes is seasonal. In the
present study, we also found seasonality; we found infec-
tion with influenza virus in 8 (88.9%) of 9 cases of NHAP that
592 T. Maruyama et al.occurred between November to March. Cytomegalovirus
can also be a causative agent of pneumonia. Papazian et al.
investigated 2785 patients of the intensive care unit with
ventilator-associated pneumonia and found pathologically
diagnosed cytomegalovirus pneumonia in 25 patients.20 In
the present study, 6.9% of the patients were also serologi-
cally positive for Cytomegalovirus although virus isolation
was not done to confirm its diagnosis.
In brief, the results of the present study showed that
examination of urinary antigen or serum antibody is useful
for diagnosis of pneumonia in non-intubated very elderly
patients, and that the primary causative organisms of
pneumonia in the very elderly population are S. pneumo-
niae and C. pneumoniae. The fact that S. pneumoniae was
more prevalent in NHAP, suggests the need to investigate
the efficacy of pneumococcal vaccination and to implement
appropriate interventions in nursing homes.Conflict of interest statement
The authors declared no conflict of interest regarding the
manuscript.
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